[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Drugs Market Research Reports & Industry Analysis

The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.

Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.

A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.

Publications found: 8,499
Sort by:

Radiation Injury (Toxicology) - Drugs in Development, 2021

US$ 2,000.00

Radiation Injury (Toxicology) - Drugs in Development, 2021 SUMMARY Radiation Injury (Toxicology) - Drugs in Development, 2021 provides an overview of the Radiation Injury pipeline landscape. The repor...

April 2021 35 pages

Radiculopathy (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Radiculopathy (Central Nervous System) - Drugs in Development, 2021 SUMMARY Radiculopathy (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Radiculopathy pipeline lands...

April 2021 30 pages

Ras (EC 3.6.5.2) - Drugs in Development, 2021

US$ 3,000.00

Ras (EC 3.6.5.2) - Drugs in Development, 2021 SUMMARY Ras (EC 3.6.5.2) - Drugs in Development, 2021 provides in depth analysis on Ras (EC 3.6.5.2) targeted pipeline therapeutics. The report provides c...

April 2021 45 pages

Raynauds Disease (Cardiovascular) - Drugs in Development, 2021

US$ 2,000.00

Raynauds Disease (Cardiovascular) - Drugs in Development, 2021 SUMMARY Raynauds Disease (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Raynauds Disease pipeline landscape. T...

April 2021 30 pages

Receptor Activity Modifying Protein 1 (Calcitonin Receptor Like Receptor Activity Modifying Protein 1 or RAMP1) - Drugs in Development, 2021

US$ 3,000.00

Receptor Activity Modifying Protein 1 (Calcitonin Receptor Like Receptor Activity Modifying Protein 1 or RAMP1) - Drugs in Development, 2021 SUMMARY Receptor Activity Modifying Protein 1 (Calcitonin R...

April 2021 35 pages

Receptor Activity Modifying Protein 3 (Calcitonin Receptor Like Receptor Activity Modifying Protein 3 or RAMP3) - Drugs in Development, 2021

US$ 3,000.00

Receptor Activity Modifying Protein 3 (Calcitonin Receptor Like Receptor Activity Modifying Protein 3 or RAMP3) - Drugs in Development, 2021 SUMMARY Receptor Activity Modifying Protein 3 (Calcitonin R...

April 2021 35 pages

Receptor Interacting Serine/Threonine Protein Kinase 1 (Cell Death Protein RIP or Receptor Interacting Protein 1 or Serine/Threonine Protein Kinase RIP or RIP1 or RIPK1 or EC 2.7.11.1) - Drugs in Development, 2021

US$ 3,000.00

Receptor Interacting Serine/Threonine Protein Kinase 1 (Cell Death Protein RIP or Receptor Interacting Protein 1 or Serine/Threonine Protein Kinase RIP or RIP1 or RIPK1 or EC 2.7.11.1) - Drugs in Deve...

April 2021 45 pages

Receptor Tyrosine Kinase (RTK) - Drugs in Development, 2021

US$ 3,000.00

Receptor Tyrosine Kinase (RTK) - Drugs in Development, 2021 SUMMARY Receptor Tyrosine Kinase (RTK) - Drugs in Development, 2021 provides in depth analysis on Receptor Tyrosine Kinase (RTK) targeted pi...

April 2021 30 pages

Recurrent Glioblastoma Multiforme (GBM) (Oncology) - Drugs in Development, 2021

US$ 2,500.00

Recurrent Glioblastoma Multiforme (GBM) (Oncology) - Drugs in Development, 2021 SUMMARY Recurrent Glioblastoma Multiforme (GBM) (Oncology) - Drugs in Development, 2021 provides an overview of the Recu...

April 2021 210 pages

Recurrent Head And Neck Cancer Squamous Cell Carcinoma (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Recurrent Head And Neck Cancer Squamous Cell Carcinoma (Oncology) - Drugs in Development, 2021 SUMMARY Recurrent Head And Neck Cancer Squamous Cell Carcinoma (Oncology) - Drugs in Development, 2021 pr...

April 2021 170 pages

Recurrent Medulloblastoma (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Recurrent Medulloblastoma (Oncology) - Drugs in Development, 2021 SUMMARY Recurrent Medulloblastoma (Oncology) - Drugs in Development, 2021 provides an overview of the Recurrent Medulloblastoma pipeli...

April 2021 40 pages

Refractory Acute Myeloid Leukemia (Oncology) - Drugs in Development, 2021

US$ 2,500.00

Refractory Acute Myeloid Leukemia (Oncology) - Drugs in Development, 2021 SUMMARY Refractory Acute Myeloid Leukemia (Oncology) - Drugs in Development, 2021 provides an overview of the Refractory Acute...

April 2021 425 pages

Refractory Angina (Cardiovascular) - Drugs in Development, 2021

US$ 2,000.00

Refractory Angina (Cardiovascular) - Drugs in Development, 2021 SUMMARY Refractory Angina (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Refractory Angina pipeline landscape...

April 2021 30 pages

Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) - Drugs in Development, 2021 SUMMARY Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) - Drugs in Development, 2021 provides an overview...

April 2021 170 pages

Refractory Medulloblastoma (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Refractory Medulloblastoma (Oncology) - Drugs in Development, 2021 SUMMARY Refractory Medulloblastoma (Oncology) - Drugs in Development, 2021 provides an overview of the Refractory Medulloblastoma pip...

April 2021 30 pages

Refractory Multiple Myeloma (Oncology) - Drugs in Development, 2021

US$ 2,500.00

Refractory Multiple Myeloma (Oncology) - Drugs in Development, 2021 SUMMARY Refractory Multiple Myeloma (Oncology) - Drugs in Development, 2021 provides an overview of the Refractory Multiple Myeloma...

April 2021 425 pages

Relapsed Acute Myeloid Leukemia (Oncology) - Drugs in Development, 2021

US$ 2,500.00

Relapsed Acute Myeloid Leukemia (Oncology) - Drugs in Development, 2021 SUMMARY Relapsed Acute Myeloid Leukemia (Oncology) - Drugs in Development, 2021 provides an overview of the Relapsed Acute Myelo...

April 2021 425 pages

Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) - Drugs in Development, 2021 SUMMARY Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) - Drugs in Development, 2021 provides an overview of...

April 2021 170 pages

Relapsed Multiple Myeloma (Oncology) - Drugs in Development, 2021

US$ 2,500.00

Relapsed Multiple Myeloma (Oncology) - Drugs in Development, 2021 SUMMARY Relapsed Multiple Myeloma (Oncology) - Drugs in Development, 2021 provides an overview of the Relapsed Multiple Myeloma pipeli...

April 2021 425 pages

Relapsing Multiple Sclerosis (RMS) (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Relapsing Multiple Sclerosis (RMS) (Central Nervous System) - Drugs in Development, 2021 SUMMARY Relapsing Multiple Sclerosis (RMS) (Central Nervous System) - Drugs in Development, 2021 provides an ov...

April 2021 45 pages

Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) - Drugs in Development, 2021 SUMMARY Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) - Drugs in Developmen...

April 2021 95 pages

Renal Cell Carcinoma (Oncology) - Drugs in Development, 2021

US$ 2,500.00

Renal Cell Carcinoma (Oncology) - Drugs in Development, 2021 SUMMARY Renal Cell Carcinoma (Oncology) - Drugs in Development, 2021 provides an overview of the Renal Cell Carcinoma pipeline landscape. T...

April 2021 375 pages

Renal Failure (Genito Urinary System And Sex Hormones) - Drugs in Development, 2021

US$ 2,000.00

Renal Failure (Genito Urinary System And Sex Hormones) - Drugs in Development, 2021 SUMMARY Renal Failure (Genito Urinary System And Sex Hormones) - Drugs in Development, 2021 provides an overview of...

April 2021 40 pages

Resistant Hypertension (Cardiovascular) - Drugs in Development, 2021

US$ 2,000.00

Resistant Hypertension (Cardiovascular) - Drugs in Development, 2021 SUMMARY Resistant Hypertension (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Resistant Hypertension pip...

April 2021 40 pages

Respiratory Depression (Hypoventilation) (Respiratory) - Drugs in Development, 2021

US$ 2,000.00

Respiratory Depression (Hypoventilation) (Respiratory) - Drugs in Development, 2021 SUMMARY Respiratory Depression (Hypoventilation) (Respiratory) - Drugs in Development, 2021 provides an overview of...

April 2021 30 pages

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Drugs in Development, 2021

US$ 3,000.00

Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Drugs in Development, 2021 SUMMARY Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Drugs in Development, 2021 provides in dept...

April 2021 95 pages

Respiratory Tract Infections (Respiratory) - Drugs in Development, 2021

US$ 2,000.00

Respiratory Tract Infections (Respiratory) - Drugs in Development, 2021 SUMMARY Respiratory Tract Infections (Respiratory) - Drugs in Development, 2021 provides an overview of the Respiratory Tract In...

April 2021 40 pages

Respiratory Tract Inflammatory Disorders (Respiratory) - Drugs in Development, 2021

US$ 2,000.00

Respiratory Tract Inflammatory Disorders (Respiratory) - Drugs in Development, 2021 SUMMARY Respiratory Tract Inflammatory Disorders (Respiratory) - Drugs in Development, 2021 provides an overview of...

April 2021 35 pages

Retinal Degeneration (Ophthalmology) - Drugs in Development, 2021

US$ 2,000.00

Retinal Degeneration (Ophthalmology) - Drugs in Development, 2021 SUMMARY Retinal Degeneration (Ophthalmology) - Drugs in Development, 2021 provides an overview of the Retinal Degeneration pipeline la...

April 2021 50 pages

Retinoic Acid Receptor (RAR) - Drugs in Development, 2021

US$ 3,000.00

Retinoic Acid Receptor (RAR) - Drugs in Development, 2021 SUMMARY Retinoic Acid Receptor (RAR) - Drugs in Development, 2021 provides in depth analysis on Retinoic Acid Receptor (RAR) targeted pipeline...

April 2021 35 pages

Retinoid X Receptor (RXR) - Drugs in Development, 2021

US$ 3,000.00

Retinoid X Receptor (RXR) - Drugs in Development, 2021 SUMMARY Retinoid X Receptor (RXR) - Drugs in Development, 2021 provides in depth analysis on Retinoid X Receptor (RXR) targeted pipeline therapeu...

April 2021 30 pages

Retinopathy (Ophthalmology) - Drugs in Development, 2021

US$ 2,000.00

Retinopathy (Ophthalmology) - Drugs in Development, 2021 SUMMARY Retinopathy (Ophthalmology) - Drugs in Development, 2021 provides an overview of the Retinopathy pipeline landscape. The report provide...

April 2021 40 pages

Reverse Transcriptase (EC 2.7.7.49) - Drugs in Development, 2021

US$ 3,000.00

Reverse Transcriptase (EC 2.7.7.49) - Drugs in Development, 2021 SUMMARY Reverse Transcriptase (EC 2.7.7.49) - Drugs in Development, 2021 provides in depth analysis on Reverse Transcriptase (EC 2.7.7....

April 2021 100 pages

Rhinitis (Ear Nose Throat Disorders) - Drugs in Development, 2021

US$ 2,000.00

Rhinitis (Ear Nose Throat Disorders) - Drugs in Development, 2021 SUMMARY Rhinitis (Ear Nose Throat Disorders) - Drugs in Development, 2021 provides an overview of the Rhinitis pipeline landscape. The...

April 2021 30 pages

Rhinosinusitis (Ear Nose Throat Disorders) - Drugs in Development, 2021

US$ 2,000.00

Rhinosinusitis (Ear Nose Throat Disorders) - Drugs in Development, 2021 SUMMARY Rhinosinusitis (Ear Nose Throat Disorders) - Drugs in Development, 2021 provides an overview of the Rhinosinusitis pipel...

April 2021 50 pages

Rho Kinase (Rho Associated Coiled Coil Forming Protein Kinase or ROCK or EC 2.7.11.1) - Drugs in Development, 2021

US$ 3,000.00

Rho Kinase (Rho Associated Coiled Coil Forming Protein Kinase or ROCK or EC 2.7.11.1) - Drugs in Development, 2021 SUMMARY Rho Kinase (Rho Associated Coiled Coil Forming Protein Kinase or ROCK or EC 2...

April 2021 50 pages

Rhodopsin (Opsin 2 or OPN2 or RHO) - Drugs in Development, 2021

US$ 3,000.00

Rhodopsin (Opsin 2 or OPN2 or RHO) - Drugs in Development, 2021 SUMMARY Rhodopsin (Opsin 2 or OPN2 or RHO) - Drugs in Development, 2021 provides in depth analysis on Rhodopsin (Opsin 2 or OPN2 or RHO)...

April 2021 30 pages

Ribonucleoside Diphosphate Reductase (Ribonucleotide Reductase or RRM or EC 1.17.4.1) - Drugs in Development, 2021

US$ 3,000.00

Ribonucleoside Diphosphate Reductase (Ribonucleotide Reductase or RRM or EC 1.17.4.1) - Drugs in Development, 2021 SUMMARY Ribonucleoside Diphosphate Reductase (Ribonucleotide Reductase or RRM or EC 1...

April 2021 65 pages

Rift Valley Fever (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Rift Valley Fever (Infectious Disease) - Drugs in Development, 2021 SUMMARY Rift Valley Fever (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Rift Valley Fever pipeline l...

April 2021 30 pages

RNA Directed RNA Polymerase (EC 2.7.7.48) - Drugs in Development, 2021

US$ 3,000.00

RNA Directed RNA Polymerase (EC 2.7.7.48) - Drugs in Development, 2021 SUMMARY RNA Directed RNA Polymerase (EC 2.7.7.48) - Drugs in Development, 2021 provides in depth analysis on RNA Directed RNA Pol...

April 2021 50 pages

RNA Polymerase I (RNAP I or Pol I or EC 2.7.7.6) - Drugs in Development, 2021

US$ 3,000.00

RNA Polymerase I (RNAP I or Pol I or EC 2.7.7.6) - Drugs in Development, 2021 SUMMARY RNA Polymerase I (RNAP I or Pol I or EC 2.7.7.6) - Drugs in Development, 2021 provides in depth analysis on RNA Po...

April 2021 30 pages

Salivary Gland Cancer (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Salivary Gland Cancer (Oncology) - Drugs in Development, 2021 SUMMARY Salivary Gland Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Salivary Gland Cancer pipeline landscape...

April 2021 70 pages

Salmonella Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Salmonella Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Salmonella Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Salmonella Infection...

April 2021 35 pages

Salmonella typhimurium Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Salmonella typhimurium Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Salmonella typhimurium Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of...

April 2021 30 pages

Sarcoidosis (Immunology) - Drugs in Development, 2021

US$ 2,000.00

Sarcoidosis (Immunology) - Drugs in Development, 2021 SUMMARY Sarcoidosis (Immunology) - Drugs in Development, 2021 provides an overview of the Sarcoidosis pipeline landscape. The report provides comp...

April 2021 45 pages

Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase 2 (Calcium Pump 2 or Calcium Transporting ATPase Sarcoplasmic Reticulum Type Slow Twitch Skeletal Muscle Isoform or Endoplasmic Reticulum Class 1/2 Ca(2+) ATPase or SERCA2 or ATP2A2 or EC 7.2.2.10) - Drugs in Development, 2021

US$ 3,000.00

Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase 2 (Calcium Pump 2 or Calcium Transporting ATPase Sarcoplasmic Reticulum Type Slow Twitch Skeletal Muscle Isoform or Endoplasmic Reticulum Class 1/2 Ca...

April 2021 35 pages

Scar (Dermatology) - Drugs in Development, 2021

US$ 2,000.00

Scar (Dermatology) - Drugs in Development, 2021 SUMMARY Scar (Dermatology) - Drugs in Development, 2021 provides an overview of the Scar pipeline landscape. The report provides comprehensive informati...

April 2021 55 pages

Schistosomiasis mansoni Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Schistosomiasis mansoni Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Schistosomiasis mansoni Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview o...

April 2021 30 pages

Schizoaffective Disorder (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Schizoaffective Disorder (Central Nervous System) - Drugs in Development, 2021 SUMMARY Schizoaffective Disorder (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Schizo...

April 2021 30 pages

Schwannoma (Non Malignant Disorders) - Drugs in Development, 2021

US$ 2,000.00

Schwannoma (Non Malignant Disorders) - Drugs in Development, 2021 SUMMARY Schwannoma (Non Malignant Disorders) - Drugs in Development, 2021 provides an overview of the Schwannoma pipeline landscape. T...

April 2021 30 pages

Filters

Search

Publishers

1
2
1
95
4
1
27
16
4
14
1
3
174
29
9
2,264
5
4
22
51
6
142
16
1
17
1
15
23
651
79
1
373
16
586
4
1
1
2
16
1,197
6
166
4
84
31
2
36
3
5
4
118
187
13
16
4
2
7
15
110
2
10
50
16
26
4
2
17
4
2
1
11
32
8
15
4
24
118
49
2
1
19
4
7
3
324
11
1
1
23
31
4
11
3
1
499
24
2
5
29
44
294
17
17
13
5
18
2

Regions

614
11
4
9
6
12
6
273
158
54
47
41
41
39
37
17
16
16
16
15
14
14
14
14
14
13
13
13
13
13
13
13
13
13
12
12
11
11
11
10
10
10
10
10
10
9
9
9
9
9
9
9
9
8
7
7
6
6
6
5
4
4
4
3
192
10
5
4
4
4
4
4
3
3
3
3
3
3
1
1
7
6
3
8
2
1
2
183
1
5
3
11
11
7
5
16
9
6
16
14
4
150
248
5,652
11

Price

Date

Pages

Offers

13
7
9
1
498